MX374829B - Composición a base de levadura para usarse para tratar cordoma. - Google Patents

Composición a base de levadura para usarse para tratar cordoma.

Info

Publication number
MX374829B
MX374829B MX2015013380A MX2015013380A MX374829B MX 374829 B MX374829 B MX 374829B MX 2015013380 A MX2015013380 A MX 2015013380A MX 2015013380 A MX2015013380 A MX 2015013380A MX 374829 B MX374829 B MX 374829B
Authority
MX
Mexico
Prior art keywords
chordoma
yeast
based composition
treat
individual
Prior art date
Application number
MX2015013380A
Other languages
English (en)
Other versions
MX2015013380A (es
Inventor
Claudia Palena
David Apelian
Jeffrey Schlom
Timothy C Rodell
Original Assignee
Globeimmune Inc
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Globeimmune Inc, Us Health filed Critical Globeimmune Inc
Publication of MX2015013380A publication Critical patent/MX2015013380A/es
Publication of MX374829B publication Critical patent/MX374829B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)

Abstract

La presente invención se refiere a un método para tratar cordoma en un individuo que tiene cordoma. El método incluye el paso de administrar a un individuo que tiene cordoma, una composición inmunoterapéutica que comprende: (a); y (b) un antígeno cancerígeno que comprende al menos un antígeno de Braquiuria. Otra modalidad de la invención se refiere al uso de una composición inmunoterapéutica que comprende un vehículo de levadura que comprende al menos un antígeno de Braquiuria para cordoma en un individuo que tiene cordoma. Aún otra modalidad de la invención se refiere al uso de una composición inmunoterapéutica que comprende un vehículo de levadura.
MX2015013380A 2013-03-19 2014-03-19 Composición a base de levadura para usarse para tratar cordoma. MX374829B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361803332P 2013-03-19 2013-03-19
PCT/US2014/031183 WO2014186047A1 (en) 2013-03-19 2014-03-19 Yeast-based immunotherapy for chordoma

Publications (2)

Publication Number Publication Date
MX2015013380A MX2015013380A (es) 2016-01-08
MX374829B true MX374829B (es) 2025-03-06

Family

ID=51898771

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015013380A MX374829B (es) 2013-03-19 2014-03-19 Composición a base de levadura para usarse para tratar cordoma.

Country Status (15)

Country Link
US (2) US10507235B2 (es)
EP (1) EP2976100B1 (es)
JP (1) JP6509808B2 (es)
KR (1) KR20150132867A (es)
CN (1) CN105228646B (es)
AU (1) AU2014265873B2 (es)
BR (1) BR112015023968A2 (es)
CA (1) CA2907560C (es)
HK (1) HK1216861A1 (es)
IL (1) IL241384B (es)
MX (1) MX374829B (es)
RU (1) RU2679806C2 (es)
SG (2) SG11201507328RA (es)
TW (2) TWI674108B (es)
WO (1) WO2014186047A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3051449A1 (de) * 2015-01-29 2016-08-03 Bayer Technology Services GmbH Computerimplementiertes Verfahren zur Erstellung eines Fermentationsmodels
AU2016302237B2 (en) * 2015-08-03 2022-08-04 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use
WO2017023840A1 (en) * 2015-08-03 2017-02-09 Globeimmune, Inc. Modified yeast-brachyury immunotherapeutic compositions

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2486400B1 (fr) 1980-07-09 1986-05-30 Univablot Medicaments a base de levures ou de leurs extraits insolubles
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4775622A (en) 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
US5310654A (en) 1985-07-31 1994-05-10 The Board Of Trustees Of The Leland Stanford Junior University Method for determining virulence of Yersinia
US5234830A (en) 1988-02-03 1993-08-10 Suntory Limited DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region
IL95019A0 (en) 1989-08-09 1991-06-10 Mycogen Corp Process for encapsulation of biologicals
US5413914A (en) 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5858378A (en) 1996-05-02 1999-01-12 Galagen, Inc. Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen
AU9589398A (en) * 1997-10-10 1999-05-03 Applied Immunotherapeutics, Inc. Cancer immunotherapy using allostimulated cells in a multiple sequential implantation strategy
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
US20020044948A1 (en) 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
US8153414B2 (en) 2000-04-06 2012-04-10 Allertein Therapeutics, Llc Microbial delivery system
WO2002039951A2 (en) 2000-11-15 2002-05-23 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
KR101241272B1 (ko) 2002-12-16 2013-03-15 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 면역 요법으로서의 효모계 백신
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US20060009404A1 (en) * 2004-07-09 2006-01-12 Williams Jason R Tumor ablation in combination with pharmaceutical compositions
SG163572A1 (en) 2005-07-11 2010-08-30 Globeimmune Inc Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
US20070172503A1 (en) 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
CA2638815A1 (en) 2006-02-02 2007-08-16 Globeimmune, Inc. Yeast-based vaccine for inducing an immune response
CA2647102A1 (en) 2006-03-27 2007-11-22 Globeimmune, Inc. Ras mutation and compositions and methods related thereto
CA2676783C (en) 2007-02-02 2016-04-05 Globeimmune, Inc. Improved methods for producing yeast-based vaccines
DK2918598T3 (en) 2007-02-28 2019-04-29 The Govt Of U S A As Represented By The Secretary Of The Dept Of Health And Human Services Brachyury polypeptides and methods of use
BRPI0809247A2 (pt) 2007-03-19 2014-09-09 Globeimmune Inc Composições e métodos para a ablação do escape mutacional de terapias marcadas para câncer.
WO2010033841A1 (en) 2008-09-19 2010-03-25 Globeimmune, Inc. Immunotherapy for chronic hepatitis c virus infection
WO2010065626A1 (en) 2008-12-02 2010-06-10 Globeimmune, Inc. Genotyping tools, methods and kits
EP3320915A1 (en) 2009-04-17 2018-05-16 Globeimmune, Inc. Combination immunotherapy compositions against cancer and methods
WO2011032119A1 (en) 2009-09-14 2011-03-17 The Regents Of The University Of Colorado Modulation of yeast-based immunotherapy products and responses
JP2013522302A (ja) 2010-03-14 2013-06-13 グローブイミューン，インコーポレイテッド 酵母系免疫療法を使用した感染症の薬理ゲノミクス及び治療反応性ガイド治療
GB201004575D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
WO2012019127A2 (en) 2010-08-05 2012-02-09 The Regents Of The University Of Colorado Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases
EP2651439B1 (en) 2010-12-17 2018-09-19 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
EP3266464A3 (en) 2011-02-12 2018-03-14 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis b infection
KR102046449B1 (ko) 2011-03-17 2019-11-19 글로브이뮨 효모-브라큐리 면역요법 조성물
EA030381B1 (ru) 2011-06-14 2018-07-31 Глоубиммьюн, Инк. Иммунотерапевтическая композиция, ее применения и способы лечения или профилактики инфекции, вызванной вирусом гепатита дельта
CA2844500C (en) 2011-08-17 2022-05-10 Globeimmune, Inc. Yeast-muc1 immunotherapeutic compositions and uses thereof
WO2017023840A1 (en) 2015-08-03 2017-02-09 Globeimmune, Inc. Modified yeast-brachyury immunotherapeutic compositions

Also Published As

Publication number Publication date
SG11201507328RA (en) 2015-10-29
RU2015144511A (ru) 2017-05-03
EP2976100A1 (en) 2016-01-27
JP6509808B2 (ja) 2019-05-08
MX2015013380A (es) 2016-01-08
CN105228646A (zh) 2016-01-06
BR112015023968A2 (pt) 2017-08-22
TWI674108B (zh) 2019-10-11
RU2679806C2 (ru) 2019-02-13
EP2976100A4 (en) 2016-10-19
AU2014265873A1 (en) 2015-10-22
TW201936206A (zh) 2019-09-16
US20160271238A1 (en) 2016-09-22
TW201446261A (zh) 2014-12-16
WO2014186047A8 (en) 2015-01-15
AU2014265873B2 (en) 2019-01-17
CA2907560C (en) 2021-12-07
IL241384B (en) 2019-12-31
US20200046818A1 (en) 2020-02-13
SG10201707608QA (en) 2017-10-30
IL241384A0 (en) 2015-11-30
EP2976100B1 (en) 2020-07-01
JP2016516081A (ja) 2016-06-02
WO2014186047A1 (en) 2014-11-20
CA2907560A1 (en) 2014-11-20
CN105228646B (zh) 2021-04-06
HK1216861A1 (zh) 2016-12-09
KR20150132867A (ko) 2015-11-26
US10507235B2 (en) 2019-12-17

Similar Documents

Publication Publication Date Title
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
TN2015000050A1 (en) Methods of treating a tauopathy
MX2020009649A (es) Anticuerpos monoclonales contra bcma.
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
MX2019015604A (es) Anticuerpos anti-tau y usos de los mismos en el tratamiento de una tauopatia.
NZ702195A (en) Anti-ly6e antibodies and immunoconjugates and methods of use
PH12016501763A1 (en) Multispecific antibodies
HK1220980A1 (zh) 用於治疗庞贝氏症的方法和组合物
EA201690617A1 (ru) Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
TN2015000396A1 (en) Antibody drug conjugates
BR112016018891A2 (pt) anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma
CO7151527A2 (es) Anticuerpos anti-cd79 b e inmunoconjugados
UY34656A (es) Polimorfos de (s)?2?(1?(9h?purin?6?ilamino)propil)?5?fluor?3?fenilquinazolin?4(3h)?ona, composición y método de preparación
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
WO2014108484A3 (en) Combination therapy of anti-her3 and anti-her2 antibodies
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
MX2016002166A (es) Anticuerpos.
AR100944A1 (es) ANTICUERPOS ANTAGONISTAS DE INTERFERÓN a Y w
MX2016004802A (es) Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
ECSP16061208A (es) Quinazolin-thf-aminas como inhibidores de pde1
EA201591709A1 (ru) 5-бром-индирубины
MX2020011946A (es) Profarmacos de antagonista de (s)-1-fenil-2-(piridin-2-il)etanamin a (nmda).
MX374829B (es) Composición a base de levadura para usarse para tratar cordoma.
GT201600082A (es) Formulaciones de inyección con base en aceite de sésamo

Legal Events

Date Code Title Description
FG Grant or registration